Raymond ScottTurnerMDPhD(He/Him)
Neurology • Washington, DCNeuroimaging, Neurodegenerative, Dementia & Geriatrics
Vice Chair for Clinical Research, Professor of Neurology, and Director of the Memory Disorders Program at Georgetown University
Dr. Turner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4000 Reservoir Road, NW
Suite 177, Building D
Washington, DC 20057Phone+1 202-687-7337Fax+1 202-784-4332
Summary
- The mission of the Georgetown University Memory Disorders Program is to prevent and treat Alzheimer's disease and related dementias by conducting innovative research, educating and training healthcare professionals and the public on research advances, and offering state-of-the-art clinical care.
Education & Training
Penn MedicinePost-Doctoral Fellowship, 1992 - 1995- University of Pennsylvania Health SystemResidency, Neurology, 1989 - 1992
- University of Pennsylvania Health SystemInternship, Internal Medicine, 1988 - 1989
Emory University School of MedicineClass of 1988, M.D.
Emory UniversityPh.D., Pharmacology, 1979 - 1984
Clemson UniversityB.S., Microbiology, Molecular Biology, with Honor, 1975 - 1979
Certifications & Licensure
DC State Medical License 2008 - 2027
VA State Medical License 2019 - 2026
MI State Medical License 1995 - 2011
PA State Medical License 1990 - 1996
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Fellow American Academy of Neurology, 2019
- Fellow (elected) American Neurological Association, 2006
- Paul Beeson Career Development Award in Aging Research American Federation for Aging Research, 1998-2001
- Join now to see all
Clinical Trials
- A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease Start of enrollment: 2019 Mar 27
- Metformin in Alzheimer's Dementia Prevention Start of enrollment: 2021 Mar 22
- AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid Start of enrollment: 2020 Jul 14
- Join now to see all
Publications & Presentations
PubMed
- Characterizing and validating 12-month reliable cognitive change in Early-Onset Alzheimer's Disease for use in clinical trials.Dustin B Hammers, Jane Musema, Ani Eloyan, Maryanne Thangarajah, Alexander Taurone
The Journal of Prevention of Alzheimer's Disease. 2025-02-15 - 2 citationsLongitudinal cognitive performance of participants with sporadic early onset Alzheimer's disease from LEADS.Dustin B Hammers, Ani Eloyan, Alexander Taurone, Maryanne Thangarajah, Sujuan Gao
Alzheimer's & Dementia. 2025-02-01 - 1 citationsDifferences in baseline cognitive performance between participants with early-onset and late-onset Alzheimer's disease: Comparison of LEADS and ADNI.Dustin B Hammers, Ani Eloyan, Maryanne Thangarajah, Alexander Taurone, Laurel Beckett
Alzheimer's & Dementia. 2025-01-01
Books/Book Chapters
Press Mentions
New Research Finds Brain Training Exercises Can Reduce Alzheimer’s SymptomsSeptember 18th, 2024
Grant Support
- Alzheimer's Clinical Trials ConsortiumNational Institute on Aging2023–2028
- Using digital signals from credit data for early detection of Alzheimer's disease and related dementiasNational Institute on Aging2023–2027
- A randomized, double blind, placebo controlled, parallel group trial to evaluate the safety and efficacy of CT1812 in early Alzheimer's disease over 18 months (START)National Institute on Aging2020–2025
- Metformin in Alzheimer's dementia Prevention (MAP)National Institute on Aging2019–2024
- The AHEAD A45 combination anti-amyloid therapy for preclinical Alzheimer's diseaseNational Institute on Aging2018–2024
- Early Onset AD Consortium - the LEADS studyNational Institute on Aging2018–2023
- AHEAD: The A3 Study: Ante-amyloid prevention of Alzheimer's diseaseNational Institute on Aging2016–2023
Committees
- Site PI, Steering Committee member, Alzheimer's Clinical Trials Consortium, University of Southern California, San Diego 2015 - Present
- Associate Editor, Reviewer, Frontiers in Neurology, Frontiers in Psychiatry, Frontiers in Neuroscience - Neurodegeneration 2009 - Present
- Site PI, Steering Committee Member, past Project PI, Alzheimer's Disease Cooperative Study, University of California, San Diego 2005 - Present
- Editorial Board Member, Reviewer, Aging, Neuropsychology, and Cognition 2000 - Present
Professional Memberships
- Fellow
- American Neurological AssociationFellow
- International Society to Advance Alzheimer's Research and Treatment (ISTAART)Member
External Links
- Memory Disorders Programhttp://memory.georgetown.edu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
